Rush MD Anderson Cancer Center is coming to Chicago. The new partnership marks University of Texas MD Anderson's seventh hospital partnership across the U.S., and is expected to expand access to clinical trials and advanced care to patients in Chicago and surrounding communities. 'Our goal is to bring our approach to team-based care and our clinical trials to communities that are far away from Houston,' Peter Pisters, MD, president of MD Anderson, the top-ranked cancer center in the nation, told Becker's. The new partnership also means Rush cancer patients will receive care that mirrors MD Anderson protocols and treatment plans.

拉什医学博士安德森癌症中心即将来到芝加哥。这项新的合作关系标志着德克萨斯大学MD安德森分校在美国建立了第七家医院合作关系，预计将扩大芝加哥及周边社区患者获得临床试验和高级护理的机会。“我们的目标是将我们的团队护理和临床试验方法带到远离休斯顿的社区，”美国排名最高的癌症中心MD安德森（MD Anderson）总裁、医学博士彼得·皮斯特斯（PeterPisters）告诉贝克尔（Becker's）。新的合作伙伴关系还意味着，拉什癌症患者将接受符合MD Anderson协议和治疗计划的护理。

Peer-to-peer connections are another core part of the partnership, with Rush providers being able to consult MD Anderson experts on best practices and treatment decisions. Already, Rush has many clinical trials that are accessible to patients, but the collaboration with MD Anderson is expected to significantly expand the number and types that are available, and ultimately bring new treatments to communities that would otherwise not be widely accessible for years. 'We have a very diverse patient population, and so the real advantage is we'll be able to offer clinical trials to our patient population and increase the accrual time, which is extremely important,' said Amina Ahmed, MD, who will serve as the director of Rush MD Anderson Cancer Center.Accrual time refers to the amount of time from when the first patient is enrolled in a study to when the last patient is enrolled.

点对点连接是合作关系的另一个核心部分，Rush提供商能够就最佳实践和治疗决策咨询MD Anderson专家。拉什已经有许多临床试验可供患者使用，但与MD Anderson的合作有望显着扩大可用的数量和类型，并最终为社区带来新的治疗方法，否则这些治疗方法将在数年内无法广泛使用。医学博士阿米娜·艾哈迈德（AminaAhmed）将担任拉什医学博士安德森癌症中心（Rush MD Anderson Cancer Center）主任，她说：“我们的患者群体非常多样化，因此真正的优势是我们能够为患者群体提供临床试验，并增加应计时间，这一点非常重要。”。应计时间是指从第一名患者参加研究到最后一名患者参加研究的时间。

The ability to both expand trial sites and enroll a more diverse patient population supports efforts to advance drug discovery, leaders said. 'We [can] create new knowledge faster and we're able to take that data set to the FDA sooner,' Dr. Pisters said. Leaders at Rush antici.

领导人说，扩大试验地点和招募更多样化患者群体的能力支持了推进药物发现的努力。皮斯特斯博士说，“我们可以更快地创造新知识，并且能够更快地将这些数据集提交给FDA。”。Rush antici的领导者。